- Investing Ideas
- U.S. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
U.S. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
7
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
7 companies
AbbVie
Market Cap: US$390.9b
A research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
ABBV
US$216.49
7D
-3.7%
1Y
16.7%
Sotera Health
Market Cap: US$4.5b
Provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally.
SHC
US$15.82
7D
-2.3%
1Y
38.9%
Travere Therapeutics
Market Cap: US$5.1b
A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
TVTX
US$55.15
7D
6.0%
1Y
285.4%
Mesa Laboratories
Market Cap: US$524.6m
Develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally.
MLAB
US$95.10
7D
-11.4%
1Y
2.3%
Waters
Market Cap: US$35.1b
Provides analytical workflow solutions in Asia, the Americas, and Europe.
WAT
US$355.44
7D
-1.2%
1Y
4.7%
BioLife Solutions
Market Cap: US$1.2b
Develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally.
BLFS
US$26.04
7D
-2.1%
1Y
21.0%
Repligen
Market Cap: US$7.4b
A life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.
RGEN
US$132.02
7D
1.1%
1Y
11.1%